Shengjing Hospital of China Medical University, Shenyang, China.
Anshan Cancer Hospital, Anshan, China.
Cancer Med. 2021 Apr;10(7):2482-2488. doi: 10.1002/cam4.3653. Epub 2021 Mar 7.
This study aims to evaluate HR-HPV viral load in the cervical lesion assessment and its diagnostic value on the triage of ASCUS. The three-step protocol for cervical cancer screening was carried out in 5171 patients from June 2017 to August 2019, and 1620 histopathological results were obtained. The positive rate of HR-HPV and TCT increased with the aggravation of pathological grades of cervical lesions. The sensitivity and specificity of HR-HPV (DH3) to detect CIN II+ were 91.91% and 84.46%, respectively. In comparison, the corresponding results of the cytology test were 80.51% and 83.12%. HPV16/18 viral load was positively correlated with the grade of cervical lesions (p < 0.001, r = 0.321). The diagnostic efficiency of AUC by applying HPV16/18 viral load was 0.682 for the diagnosis of CIN II+. The optimal HPV16/18 viral load for predicting CIN II+ was 6.80 RLU/CO (relative light units/cut-off), with corresponding sensitivity of 48.6%, specificity of 79.7%, and Youden index of 0.283. In the ASCUS population, viral loads were statistically different in HPV16/18 and the other 12 HR-HPV when compared cervicitis group with CIN I group and CIN II+ group (all p < 0.05). Statistical differences were detected concerning HPV16/18 viral load, contact bleeding status, and smoking status when compared cervicitis group with CIN I group and CIN II+ group (p < 0.05), with a corresponding odds ratio of 1.004, 1.533, and 5.513, respectively. Our findings suggest that HR-HPV viral load can be regarded as a useful tool to predict the grade of cervical lesions for ASCUS triage. ClinicalTrials.gov ID: NCT03178136.
本研究旨在评估 HR-HPV 病毒载量在宫颈病变评估中的作用及其对 ASCUS 患者分流的诊断价值。我们对 2017 年 6 月至 2019 年 8 月间的 5171 例患者进行了宫颈癌筛查三步法,并获得了 1620 例组织病理学结果。随着宫颈病变病理分级的加重,HR-HPV 和液基细胞学(TCT)的阳性率逐渐升高。HR-HPV(DH3)检测 CIN II+的灵敏度和特异度分别为 91.91%和 84.46%,细胞学检查的相应结果分别为 80.51%和 83.12%。HPV16/18 病毒载量与宫颈病变程度呈正相关(p<0.001,r=0.321)。应用 HPV16/18 病毒载量的诊断效率对 CIN II+的诊断曲线下面积(AUC)为 0.682。用于预测 CIN II+的最佳 HPV16/18 病毒载量为 6.80RLU/CO(相对光单位/临界值),此时的灵敏度为 48.6%,特异度为 79.7%,Youden 指数为 0.283。在 ASCUS 人群中,与宫颈炎组相比,HPV16/18 和其他 12 种高危型 HPV 在 CIN I 组和 CIN II+组间的病毒载量差异有统计学意义(均 p<0.05)。与宫颈炎组相比,HPV16/18 病毒载量、接触性出血和吸烟状态在 CIN I 组和 CIN II+组间差异有统计学意义(均 p<0.05),对应的比值比分别为 1.004、1.533 和 5.513。本研究表明,HR-HPV 病毒载量可作为预测 ASCUS 患者宫颈病变程度的有用工具。临床试验注册编号:NCT03178136。